Volta Medical, a leading health technology company specializing in artificial intelligence (AI) solutions for electrophysiologists, has announced a Joint Development Agreement with GE HealthCare, a global leader in medical technology, pharmaceutical diagnostics, and digital solutions.

This collaboration aims to integrate Volta’s AI solution, the Volta AF-Xplorer™, with GE HealthCare’s Prucka™ 3 and CardioLab™ EP Recording system.

The combined technologies are expected to enhance performance and streamline workflows for electrophysiologists during catheter ablation procedures to treat atrial fibrillation (AFib).

"They has mission to combat complex heart rhythm diseases relies on optimizing interoperability.

Through this collaboration with GE HealthCare, They are advancing the frontier of current clinical applications in the field of electrophysiology."

"By integrating AI solution with EP innovators, They aim to increase compatibility and address the challenges clinicians face in analyzing cardiac electrical signals to enhance patient care."

Volta Medical’s AI solution assists electrophysiologists in real-time assessment of dispersed electrograms (EGMs), which aligns with GE HealthCare's CardioLab™ EP Recording system’s capability to provide clear signals.

The integration of these technologies aims to help physicians optimize the management of AFib by combining advanced EP recording capabilities with AI-driven dispersion information.

"Access to vast amounts of data empowers clinicians in their decision-making, but effectively using this data at the point of care can be challenging."

"As GE HealthCare continues to advance innovation to provide clinicians with precise signals in the electrophysiology lab, Volta Medical’s AI-driven solutions hold promise in consolidating and simplifying data, as well as assisting clinicians in making treatment decisions for their patients.

They excited about ongoing collaboration with Volta Medical as they work to innovate and transform electrophysiology labs to ensure patients receive the best possible care."

This collaboration follows Volta’s key initiatives presented at the Heart Rhythm Society 2024 meeting, where the positive TAILORED-AF trial results were showcased. These results demonstrated improved freedom from AFib in patients treated with AI-guided ablation compared to conventional anatomical ablation.

Volta Medical is now focusing on early commercialization efforts and completing the RESTART clinical trial, which is evaluating the use of Volta’s AI ablation solution in patients with recurrent AFib who failed previous ablations and are now undergoing Volta-supported ablation.

The American Heart Association defines AFib as a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure, and other heart-related complications.

Approximately 33 million people worldwide live with AFib. Despite the severe risks associated with untreated AFib, including a doubled risk of heart-related deaths and a fivefold increased risk of stroke, many patients are unaware of the seriousness of the condition.

 

 

 

 

Source: volta-medical.eu

Report Abuse